Otsuka Pharmaceutical Co., Ltd.
Pharmaceuticals
May 8, 2012
T1xbet 카지노 Federal Circuit Decision Affirming t1xbet 카지노 Validity of t1xbet 카지노 Asserted Claims of Otsuka's Patent to ABILIFY®
Tokyo, Japan, May 8, 2012 - Otsuka Pharmaceutical Co., Ltd. and Otsuka Holdings, Co., Ltd., t1xbet 카지노 parent company of Otsuka Pharmaceutical Co., Ltd., announced today that t1xbet 카지노 U.S. Court of Appeals for t1xbet 카지노 Federal Circuit issued its judgment dated May 7, 2012 in favor of Otsuka Pharmaceutical Co., Ltd. in its patent litigation against several companies seeking FDA approval to market generic copies of ABILIFY®
T1xbet 카지노 Federal Circuit affirmed t1xbet 카지노 only issue on appeal from t1xbet 카지노 district court's decision, holding that t1xbet 카지노 asserted claims of U.S. Patent No. 5,006,528 covering aripiprazole, t1xbet 카지노 active ingredient in ABILIFY®, are valid, thus maintaining patent and regulatory protection for ABI® in t1xbet 카지노 United States until at least April 20, 2015.
Otsuka Pharmaceutical will keep striving to contribute to t1xbet 카지노 welfare of patients suffering from mental illness through maximizing t1xbet 카지노 t1xbet 카지노rapeutic value of ABILIFY®.
Latest Pharmaceutical Business related News Releases